75 related articles for article (PubMed ID: 27229159)
1. Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus 'GoraVir' for the treatment of pancreatic ductal adenocarcinoma.
Bots STF; Harryvan TJ; Groeneveldt C; Kinderman P; Kemp V; van Montfoort N; Hoeben RC
Mol Oncol; 2024 May; 18(5):1245-1258. PubMed ID: 38037840
[TBL] [Abstract][Full Text] [Related]
2. Properties of Adenovirus Vectors with Increased Affinity to DSG2 and the Potential Benefits of Oncolytic Approaches and Gene Therapy.
Bahlmann NA; Tsoukas RL; Erkens S; Wang H; Jönsson F; Aydin M; Naumova EA; Lieber A; Ehrhardt A; Zhang W
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016457
[TBL] [Abstract][Full Text] [Related]
3. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ
PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome Analysis of Ovarian and Uterine Clear Cell Malignancies.
Alldredge J; Randall L; De Robles G; Agrawal A; Mercola D; Liu M; Randhawa P; Edwards R; McClelland M; Rahmatpanah F
Front Oncol; 2020; 10():598579. PubMed ID: 33415077
[TBL] [Abstract][Full Text] [Related]
5. CD46 and Oncologic Interactions: Friendly Fire against Cancer.
Elvington M; Liszewski MK; Atkinson JP
Antibodies (Basel); 2020 Nov; 9(4):. PubMed ID: 33147799
[TBL] [Abstract][Full Text] [Related]
6. Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.
Gonzalez-Pastor R; Goedegebuure PS; Curiel DT
Cancer Gene Ther; 2021 May; 28(5):375-389. PubMed ID: 32951021
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity.
Hajeri PB; Sharma NS; Yamamoto M
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526919
[TBL] [Abstract][Full Text] [Related]
8. Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor.
Kuryk L; Møller AW
J Med Virol; 2020 Aug; 92(8):1309-1315. PubMed ID: 31944306
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses.
Hoare J; Campbell N; Carapuça E
Porto Biomed J; 2018 Aug; 3(1):e7. PubMed ID: 31595233
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the development of gene delivery systems.
Sung YK; Kim SW
Biomater Res; 2019; 23():8. PubMed ID: 30915230
[TBL] [Abstract][Full Text] [Related]
11. Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection.
Bourhill T; Mori Y; Rancourt DE; Shmulevitz M; Johnston RN
Viruses; 2018 Aug; 10(8):. PubMed ID: 30103501
[TBL] [Abstract][Full Text] [Related]
12. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.
Uusi-Kerttula H; Davies J; Coughlan L; Hulin-Curtis S; Jones R; Hanna L; Chester JD; Parker AL
Oncotarget; 2016 May; 7(19):27926-37. PubMed ID: 27056886
[TBL] [Abstract][Full Text] [Related]
13. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.
Greig JA; Buckley SM; Waddington SN; Parker AL; Bhella D; Pink R; Rahim AA; Morita T; Nicklin SA; McVey JH; Baker AH
Mol Ther; 2009 Oct; 17(10):1683-91. PubMed ID: 19603000
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD46 Enhances Anti-Tumoral Activity of Adenovirus Type 5 for Bladder Cancer.
Do MH; To PK; Cho YS; Kwon SY; Hwang EC; Choi C; Cho SH; Lee SJ; Hemmi S; Jung C
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30201920
[TBL] [Abstract][Full Text] [Related]
15. A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.
Yang M; Yang CS; Guo W; Tang J; Huang Q; Feng S; Jiang A; Xu X; Jiang G; Liu YQ
Cancer Biol Ther; 2017 Nov; 18(11):833-840. PubMed ID: 29144842
[TBL] [Abstract][Full Text] [Related]
16. [Characterization of adenovirus serotype 35 vectors using genetically modified animals and non-human primates].
Sakurai F; Kawabata K; Mizuguchi H
Yakugaku Zasshi; 2006 Nov; 126(11):1013-9. PubMed ID: 17077607
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.
Hulin-Curtis SL; Uusi-Kerttula H; Jones R; Hanna L; Chester JD; Parker AL
Cancer Gene Ther; 2016 Jul; 23(7):229-34. PubMed ID: 27229159
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
